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Overexpression of aminopeptidase A abolishes the growth promoting
effects of angiotensin II in cultured mouse mesangial cells. Angiotensin 11
(Ang TI) has diverse effects on the glomerular tuft such as regulation of
glomerular hemodynamics and stimulation of mesangial cell growth, and
may be one pivotal factor in the progression of renal disease. In order to
locally inactivate Aug II, we overexpressed aminopeptidase A (E.G.
3.4.11.7; ATA), a peptidase involved in the conversion of Ang II into
angiotensin III, in a mouse mesangial cell line (MMC) that normally does
not exhibit this enzyme. Stable transfections were selected in medium
containing G418. ATA-overexpressing clones ATA5 and ATA21 revealed
mRNA, protein, and enzyme activity in contrast to wild-type MMCs or
mock-transfected Neo3 cells (stably transfected with expression vectors
without ATA eDNA). There was no difference in the binding of Ang II to
its putative receptors in all cell lines. Ang TI increased intracellular inositol
1,4,5-triphosphate (1P3) in Neo3, but not in ATM and ATA21 cells. In
contrast to MMCs and Neo3 cells, Ang II failed to stimulate proliferation
in ATA5 and ATA2I clones as measured by [3H1 thymidine incorporation
and direct cell counts. However, ATA5 and ATA2I revealed a mitogenic
response not different from MMCs after stimulation 2% or 10% of fetal
calf serum. Treatment of ATA5 and ATA21 with 0.1 mu of the ATA-
inhibitor amastatin or an ATA-inhibiting specific monoclonal antibody
restored the proliferative effect of Ang II, suggesting that surface activity
of ATA is involved in the attenuated mitogenesis in these cell. Our study
demonstrates that it is feasible to overexpress Ang IT-degrading enzymes
in cultured mesangial cells and that this overexpression attenuated some
effect of exogenous Aug II. These experiments are a first step toward the
development of novel strategies to selectively antagonize locally generated
Ang II in the kidney.
Angiotensin II (Ang Ii) is currently viewed as one major factor
being involved in the progression of chronic renal disease [1—8].
In the glomerular microenvironment, the octapeptide has been
implicated in such diverse functions such as regulation of glomer-
ular hemodynamics and glomerular ultrafiltration, mesangial up-
take and processing of macromolecules, stimulation of mesangial
growth and synthesis of extracellular matrix components such as
collagens, and chemoattraction of immune competent cells into
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the glomerular tuft [1—7]. The most direct proof of the detrimental
actions of Ang II on the glomerulus may stem from investigations
in rats that overexpress angiotensinogen and renin in the glomer-
ulus [91. These animals developed irreversible glomeruloscierosis
without hypertension, suggesting that Ang II growth promoting
effects may play a pivotal role in these structural alterations [9].
Although several substances, including angiotensin converting
enzyme (ACE) inhibitors as well as the new non-peptide Ang
IT-receptor antagonists, could effectively interfere with Ang Ii's
action, there is recent evidence of an independent renal renin-
angiotensin system (RAS) that may not be necessarily inhibited by
the commonly used concentrations of these drugs [3, 7].
In the present study, we have applied a different approach to
locally inactivate Ang II. Cultured murine mesangial cells (MMC)
were stably transfected with an expression plasmid in order to
overexpress aminopeptidase A (E.C. 3.4.11.7; ATA). ATA is an
Ang II degrading enzyme and is normally expressed in the kidney
in mouse podocytes as well as proximal tubular epithelia cells, but
not in mesangial cells [10]. The overexpression of ATA in MMCs
abolished the mitogenic action of Ang II normally observed in
these cells, but was without effect on Ang Il-receptor expression
or proliferative response induced by other mitogens. Our studies
demonstrate that it is feasible to overexpress an Aug Il-splitting
enzyme to antagonize the actions of this vasopeptide presumably
by its faster degradation.
METHODS
Cell culture
Mouse mesangial cells (MMCs) are a SV 40-transformed cell
line originally isolated from 8- to 10-week-old naive SJL/J (H2s)
mice [11]. These cells possess many features of differentiated
mesangial cells including expression of Ang Il-receptors and a
Fc-receptor for immunoglobulins, and have been extensively
characterized [11—141. MMCs were grown in Dulbecco's Modified
Eagle's medium (DMEM; Gibco-BRL, Eggenstein, Germany)
containing 450 mg/dl glucose, 100 U/mI penicillin, 100 .tgIml
streptomycin, 5 mvt glutamine, and 10% decomplemented fetal
calf serum (FCS; Gibco-BRL). Cells were grown in 5% CO2 and
passaged every 48 to 72 hours by trypsinization.
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Transfection procedures and selection of ATA overexpressing
clones
For ATA overexpression, 106 MMCs were cotransfected with
10 g of each SRaBP-l (gift of Max D. Cooper, University of
Alabama, Birmingham, AL, USA) [15] and 5 jig pHook-1 (In-
vitrogen, Leek, Netherlands) using calcium phosphate. The
SRaBP-1 plasmid contains a full-length cDNA encoding for BP-l,
the mouse ATA, driven by the SRa promoter that is composed of
the SV 40 early promoter and the R segment, and is part of the U5
sequence of the long terminal repeat of human T-cell leukemia
virus type I [16]. The SRaBP-1 construct has been previously used
to express ATA in COS-7 and Ltk— cells [15]. Besides a neomycin
resistance, the pHook-1 plasmid expresses a single-chain antibody
(sFv) to a specific hapten (see below) being displayed on the
surface of transfected cells. Twenty-four hours after transfection,
cells were released from the plate by light trypsinization, washed,
and were collected in a 1.5 ml cup. Cells were mixed with 1.5 x
106 magnetic beads bearing the phOx (4-rthoxy-methylene-2-
phenyl-2-oxazolin-5-one) hapten on their surface (Capture beads;
Invitrogen). After incubation with slow rotation (5 revolutions per
mm) for 30 minutes at 37°C, the beads were pelleted with a
magnetic stand (Invitrogen). Non-selected cells were removed,
pellets were washed in serum-free DMEM, and the pelleting was
repeated with the magnetic stand. This washing step was repeated
twice. Finally, cells were plated at low-density into a 96-well plate
in DMEM with 10% FCS. After another 24 hours, the medium
was changed and 600 jig/ml of G418 (Gibco-BRL) were added to
select for stable transfectants. In pilot experiments we established
that this concentration of G418 was toxic for wild-type MMCs.
After one week, surviving cells were cloned by limiting dilution
and replated in 96-well plates in the presence of G418. Estab-
lished cultures were maintained in medium with 600 jig/mI G418
to prevent back mutations. In general, no G418 was used for
proliferation experiments and enzyme measurements.
In addition, control cell lines were established by transfecting
MMCs with an SRcx vector [16] without a BP-1 insert and the
pHook-1 plasmid. Selection of sFV bearing cells and limiting
dilution in G418 containing medium was performed as described
above. Control cell lines were designated as Neo.
RT-PCR for aminopeptidase A and Northern blotting
Stable transfectants were initially screened for ATA transcripts
by eDNA amplification of reverse transcribed total RNA. There-
fore, a total of 106 cells were lysed in 5 ml of a buffer containing
4 M guanidine thiocyanate, 25 mM sodium citrate (pH 7.0), 0.5%
sodium lauroyl-sarcosinate, and 0.7% j3-mercaptoethanol. Total
RNA was extracted by repetitive phenol-chloroform extraction
and was precipitated with ice-cold isopropranolol [12]. For re-
verse transcription, 5 jig of total RNA in 7.5 jil water were
incubated at 65°C for three minutes, and subsequently 5.5 jil
first-strand buffer (250 mtvt Tris-HCI, 375 mrvi KC1, 15 m'vi MgCI2),
3.4 jil deoxynucleotide triphosphates (dNTP, 10 m of each), 2.7
jil 0.1 M dithiothreitol, 0.5 jig Poly-dT-primer (Pharmacia,
Frciburg, Germany), 14 U RNAsin (Promega, Madison, WI,
USA), and 200 U M-MLV Reverse Transcriptase (Gibco-BRL)
were added, and the reaction was incubated at 37°C for 90
minutes. After first-strand eDNA synthesis, the reaction mix
was precipitated with 7.5 M ammonium acetate and isopropanol.
The pellets were washed in 70% ethanol and resuspended in
50 jil water. Five microliters of each eDNA and 150 ng of the
following primers were used: mouse ATA, 5'GACGTACTTTC-
AAGGCCAAGTG3'; 5 'GCTGCAGTTCAGTGTTGAAGGG3'
[17]; GAPDH, 5 'AATGCATCCTGCACCACCAA3', 5 'GTAGC-
CATATTCATTGTCATA3' [18]. The predicted sizes of the
amplification reactions were 563 bp for ATA, and 521 bp for
GAPDH. Amplification reactions were performed exactly as
described previously [19] with 0.2 M of each dNTP and 2.5 U of
Taq polymerase (Perkin Elmer Cetus, Ueberlingen, Germany) in
amplification buffer (20 mM Tris-HCI, pH 8.3; 25 mi KCI, 2.0 mM
MgCI,, 0.05% Tween 20). Amplifications for mouse ATA and
GAPDH was performed in separate tubes. Thirty-five cycles with
a denaturation step for 92°C for one minute, an annealing step of
56°C for 1.5 minutes, and an extension step at 72°C for 1.5 minutes
were performed. Ten microliters of each reaction product were
run on a 1.5% agarose gel containing 0.5 jig/mI ethidium bromide.
To confirm the results obtained from RT-PCR by Northern
blotting, 20 jig of total RNA was electrophoresed through a 1.2%
agarose gel with 2.2 M formaldehyde. The RNA was vacuum
blotted onto a nylon membrane (Zetabind; Cuno, Meriden, CT,
USA) and UV cross-linked. For the detection of mouse ATA
transcripts, a 3.5 kilobase fragment of the eDNA BP-1 (also a gift
of Max D. Cooper) [17] was labeled using random primers. For
control hybridization after stripping, a 2.0 kilobase insert of the
plasmid pMC1 encoding the mouse 18S RNA band was used.
Hybridization, washing, and stripping procedures were performed
exactly as previously described [12, 13].
Angiotensin It-receptor expression
To test whether ATA overexpressing cells may exhibit a differ-
ent expression pattern of Ang lI-receptors, RT-PCR for the
AT1-receptor as well as competition binding studies were per-
formed. RT-PCR was executed for 35 cycles as described above
(same temperature profile) with the following primers for the
AT1 -receptor: 5 GATAA'TTATGGCGATTGTG3' and 5' GTA-
AGAAAGCGTGCTCATTFTCG3' [20]. The predicted size of
the amplified product was 238 bp. Hybridization of an end labeled
internal primer to the amplification product revealed the correct
nature of the product (data not shown). For control reactions, the
following primers for mouse /3-actin were used: 5'GGCCAAGT-
CATCACTATTGG3' and 5' GGACTCATCGTACTCCTGC3'.
Reactions were independently (RNA isolation, reverse transcrip-
tion, and eDNA amplification) performed four times with quali-
tatively similar results.
Binding studies were carried out on 5 X i0 cells grown to
subconfluence in 24-well culture plates in assay buffer consisting
of 150 mivi NaC1, 5 ms MgC12, 50 mi Tris-HCI (pH 7.1), 5 mi
EDTA, 0.7% bovine serum albumin, 0.5% aprotinin, 1 m'vi
phenylmethylsulfonyl fluoride (PMSF), and 0.5 mM amastatin
(Sigma, Deisenhofen, Germany) to inhibit potential ATA activity
in overexpressing clones [211. For displacement experiments, 0.5
M [tyrosyl-3,5-3H-angiotensin 11(30 to 60 Ci/mmol; Amersham,
Braunschweig, Germany) was incubated in the presence or ab-
sence of io to iO M cold Ang II (Sigma) for two hours on a
shaking platform at 22°C. At the end of the incubation period,
cells were washed three times in ice-cold PBS, precipitated in 10%
trichloracetic acid, and proteins were redissolved in I N NaOH.
Radioactivity was determined by liquid scintillation spectroscopy.
Nonspecific binding was determined in the presence of 10 M
non-radioactive Ang II and was less than 10% of total binding.
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Specific binding in the absence of cold competitor was considered
to be 100%. Experiments were repeated four times with duplicate
measurements for each experiment.
Aminopeptidase A enzyme activity
Aminopeptidase A (ATA) surface enzyme activities were mea-
sured on subconfluent cells in 24-well plates rested for 24 hours in
serum-free DMEM. For this reason, IO cells were incubated for
one hour in 1 ml of a substrate solution containing 17.5 mM
aipha-glutamyl-nitranilide (Serva, Heidelberg, Germany) in 0.5 M
Tris-HC1 (pH 7.2) supplemented with 10 m calcium chloride. At
the end of the incubation, cells were washed in PBS, lysed, and the
protein content was determined by the Lowry method. Absorption
of substrate solution was immediately measured at 405 nm against
the substrate solution as blank. ATA activity was calculated as
described and is expressed in pUImg cellular protein [22].
Western blotting
A total of i0 quiescent cells of the various clones were washed
in ice-cold PBS and scraped off the culture flask in disruption
buffer (2% SDS, 60 mi Tris-HC1, pH 6.8; 100 mt dithiothreitol,
0.5% aprotinin, and 0.5 m'vi PMSF). Protein concentrations were
adjusted to 100 jtgIsample, 5% glycerol/0.03% bromophenol blue
were added, and samples were boiled for 10 minutes. After
centrifugation, supernatants were loaded onto a denaturing 8%
SDS-polyacrylamide gel. Molecular weight markers (High molec-
ular Rainbow markers, Amersham) that comprise 14,300 to
200,000 Daltons served as molecular weight standards. After
completion of electrophoresis, proteins were electroblotted onto a
nitrocellulose membrane (Highbond-N; Amersham) in transfer
buffer (50 ms'i Tris-HCI, pH 7.0; 380 mi glycine, 0.1% SDS, 20%
methanol). Membranes were blocked for one hour at 22°C with
5% nonfat dry milk redissolved in PBS with 0.1% Tween 20. For
the detection of ATA, a 1:500 dilution of the rat monoclonal
antibody ASD-4 generated against mouse ATA was used as a
primary antibody. The generation and characterization of this
antibody has been previously described [23, 24]. A horseradish
peroxidase-conjugated polyclonal rabbit anti-rat antibody (Sigma)
was used as a secondary antibody. The ECL reagent (Amersham)
was applied according to the recommendations of the manufac-
turer to visualize peroxidase. Western blots were repeated twice.
Immunofluorescence
Cells were grown in glass slide chambers (Nunc, Roskilde,
Denmark) to subconfluence. Cells were then fixed at —20°C in
acetone for 10 minutes before their staining. Slides were incu-
bated with a 1:20 dilution of the monoclonal ASD-4 antibody for
one hour in a wet chamber. After washing in PBS with 0.5%
albumin, the stain was developed with a 1:50 diluted FITC-labeled
rabbit anti-rat IgG antiserum (Miles Scientific, Munich, Germa-
ny).
Intracellular inositol trisphophate concentrations
ATA5, ATA21 and Neo3 cells (2 >< 10) were plated into
six-well plates, rested for 24 hours in serum-free medium, and
subsequently stimulated for 10 minutes with l06 M Ang II. In
addition, to inhibit ATA enzyme activity in ATA2lcelIs, 20 jii of
ascites of the monoclonal anti-murine ATA antibody ASD-4 were
added per well 30 minutes prior to challenge with control medium
or Ang II. This antibody has been previously shown to inhibit
ATA enzyme activity [23, 24]. Some ATA21 cells were also
treated with 106 M of angiotensin III (Ang III; Sigma). The
incubation was terminated with 15% trichloracetic acid, and
supernatants of lysed cells were extracted three times with 10 vol
water-saturated diethyl ether and then titrated to pH 7.5 with I M
NaHCO3. Cells were counted in parallel wells. Intracellular
inositol 1,4,5-trisphosphate (1P3) was measured in duplicate from
each experiment (N = 4 to 5 independent experiments) directly in
the neutralized supernatants with a commercial radioimmunoas-
say according to the manufacturer's recommendations (Biotrak'°
from Amersham). Data are expressed as picomoles of 1P3 per IO
cells.
Cellular proliferation
A total of i0 cells of the various lines were transferred to each
well of a 96-well plate and were made quiescent in DMEM
without FCS and G418. Cells were then incubated for 24 hours
with a single dose of 10_8 to i0' M Ang II. This dose was shown
earlier to be mitogenic for MMCs [ii, 12]. To test for the effect of
ATA expression, enzyme activity was inhibited for some experi-
ments with 0.1 mr't amastatin. In order to inhibit ATA more
specifically, ATA5 and ATA21 cells were incubated in the pres-
ence of 2 jd per well (96-well plate) of ascites of the monoclonal
anti-murine ATA antibody ASD-4. For these experiments, cells
incubated in control medium without Ang II also received the
same amount of antibody to control for nonspecific effects.
Additional cells received DMEM with either 2% or 10% FCS.
Moreover, all cell lines were also treated with a single dose of
either Ang III or angiotensin IV (Ang ll-(3-8) = Ang IV; Sigma).
Cells were pulsed with 1 Ci per well [3H]thymidine (5 Ci/mmol,
Amersham) for the last six hours of culture. At the end of the
incubation, cells were washed once in PBS, trypsinized for 10
minutes at 37°C, and finally collected on glass-fiber paper with an
automatic cell harvester. Radioactivity of dry filters was deter-
mined by liquid scintillation spectroscopy in the presence of
scintillation cocktail (Roth, Karisruhe, Germany). [3H] thymidine
incorporation experiments were independently repeated five to six
times in duplicate. For direct cell counts, iO cells were trans-
ferred into each well of a 24-well plate, rested for 24 hours in
serum-free DMEM without G418, and stimulated for another 48
hours with iO to 106 M Ang II. At the end of the incubation
period, cells were trypsinized, and counted in a Neubauer cham-
ber by an investigator blinded to the protocol. Direct cell count
experiments were independently repeated six times in duplicate.
Statistical analysis
All data are presented as the means SEM. Statistical signifi-
cance between different groups was first tested with the non-
parametric Kruskal-Wallis test. Individual groups were subse-
quently tested using the Wilcoxon-Mann-Whitney test. A P value
of < 0.05 was considered significant.
RESULTS
Establishment and characterization of aminopeptidase A
overexpressing mesangial cells
A total of twenty surviving G418 clones were screened by
RT-PCR two weeks after transfcction. From these clones, seven
showed an amplification product of the expected 563 base pairs.
Figure 1 shows an example of a eDNA amplification after reverse
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— ATA5 glycosylated form of ATA with exactly the same molecular weight
under reducing conditions [23, 24]. Immunofluorescence studies
— MMC revealed
that no specific ATA staining could be detected in
untransfected, wild-type MMC (Fig. 4A). However, a strong
— Standard nuclear as well surface staining was present with the ASD-4
antibody in the ATA overexpressing clone ATA5 (Fig. 4B). A
similar staining pattern was present in ATA21 cells (data not
shown). Staining of cells with only the secondary antibody re-
vealed no specific labeling of the cells (data not shown). To test
whether ATA overexpressing cells also increase their enzymatic
activity, alpha-glutamyl-nitranilide was used as a sensitive sub-
strate for ATA in accordance with previous studies [22]. In
agreement with other studies [25], we decided to evaluate surface
ATA activity on growing monolayers of cells, since only the
surface displayed activity may be involved in the degradation of
Ang II before binding the peptide to its putative receptors. MMCs
revealed an ATA enzyme activity of 50 10 JLU/mg protein (N =
6), which was close to the detection level of the assay and probably
reflects metabolism of the substrate alpha-glutamyl-nitranilide by
peptidases other than ATA. In contrast, ATA enzyme activity
could be easily measured in ATA5 (290 10 iU/mg protein, N =
6) and ATA21 (900 30 RU/mg protein, N = 6) cells and was
significantly higher compared with MMCs (P < 0.001).
Expression of angiotensin II receptors in the various cell lines
Fig. 1. Example of the initial screening procedure for aminopeptidase A
(ATA)-overexpressing cells using RT.PCR. In contrast to wild-type mouse
mesangial cells (MMCs), the clone ATA5 revealed an expected band of
563 bp. Amplification of cDNA with primers for the housekeeping gene
GAPDI-I showed products in ATM and MMC indicating successful RNA
isolation and reverse transcription. A DNA ladder as a weight marker is
shown on the right (400 to 800 bp).
transcription of total RNA. In contrast to the clone ATA5,
wild-type MMCs did not express ATA transcripts (Fig. 1). To
confirm transgene expression, Northern blotting was performed
with total RNA from all initially positive clones five weeks after
transfections, including RNA from untransfected MMCs and the
clone Neo3, which was established by transfecting MMCs with
SRa vector without an insert and pHook-1. As depicted in Figure
2, only the cell lines ATA5, ATA1O, and ATA21 from the original
seven positive cell clones identified by RT-PCR displayed tran-
scripts on Northern blot, indicating that the transgene is lost from
some cells during prolonged culture. Neo3 cells (mock transfec-
tions with the SRa and pHook-1 vectors only) and wild-type
MMCs revealed no specific hybridization for mouse ATA. The
slight difference in the size of the hybridization signal in the clones
ATAS, ATAJO, and ATA2O may be due to a homologous
recombination at different sites or different splicing of mRNA in
the various cell clones (Fig. 2). The cell lines ATM and ATA21
were selected for further studies. We next tested whether the
transfected cells produce ATA protein. To this end Western blots
were performed. Figure 3 illustrates that the clones ATA5 and
ATA21, but not Neo3 and MMC express a specific protein band
of 130 kDa when the blots were probed with the monoclonal
antibody ASD-4 that is directed against mouse ATA. Previous
studies have shown that this antibody recognized the monomeric
To test the possibility that ATA overexpression may alter the
affinity and abundance of endogenous Ang TI-receptors, we
performed receptor binding analysis by displacement studies and
evaluated AT1-receptor transcripts in the various cell lines. As
demonstrated in Figure 5A, there was no significance difference in
binding characteristics of Ang II to its putative receptors in MMC,
ATA5, ATA21 and Neo3 cells. To prevent potential degradation
of the tracer by ATA, binding assays were done in the presence of
0.5 mM amastatin, a potent inhibitor of ATA. Amastatin was also
included in binding assays in MMCs and Neo3 cells in order to
have similar assay conditions in all cell lines. Since MMCs express
only AT1 -receptors, RT-PCR for transcripts of this subtype of
Ang 11-receptors was performed in all cell lines. This approach
was not selected to quantitate absolute amounts of AT1-receptor
mRNA expression, but rather served to demonstrate that AT1-
transcript expression was not absent in the transfected cell lines.
Although there was some variation in the abundance of AT1-
receptor transcripts compared with /3-actin mRNA expression
among all tested cells, there was no real correlation with the
results obtained from binding studies, suggesting that small dif-
ferences in transcript levels as detected by eDNA amplification do
not alter binding characteristics of Aug II (Fig. SB).
Intracellular 1,4,5-triphosphate concentrations
To test whether signal transduction pathways for Ang II may
differ in the three cell lines, we measured 1P3, which is a typical
second messenger for Ang II in mesangial cells. As shown in Table
1, Ang II strongly stimulated generation of 1P3 in Neo3 cells. In
contrast, the peptide failed to activate this signal transduction
pathway in ATA5 and ATA21 cells (Table 1). However, 1P3
generation occurred when ATA21 cells were challenged with Ang
II in the presence of an ATA neutralizing monoclonal antibody
(Table 1). Ang III had no effect on 1P3 synthesis in ATA2T cells.
ATA
GAPDH
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Neo3
Angiotensin lI-stimulated proliferation in the various cell lines
We have previously shown that Ang II has a small, but
significant proliferative effect on MMCs in serum-free DMEM in
the absence of other growth factors [11, 12]. As predicted, a single
dose of 10_5106 M Ang II for 24 hours leads to a significant
increase in [3Hthymidine in MMCs (Fig. 6). In addition, the
mock-transfected Neo3 cell line showed a similar behavior. In
contrast, the same concentration of Ang 11 failed to stimulate
proliferation in ATA5 and ATA21 cell lines (Fig. 6). Further-
more, this observation was also present when total cell counts
were evaluated after 48 hours of Ang II stimulation (Table 2).
However, other mitogens such as FCS induced proliferation in
ATA5 and ATA2I cells to a similar extent as in MMCs, indicating
that a failure to proliferate is not intrinsic to ATA5 and ATA21
cells (Table 3). When 0.1 m of the ATA inhibitor amastatin was
added to the culture medium, iO M Ang TI-induced prolifera-
tion of ATA5 and ATA21 cells (Table 4). However, since
amastatin may also inhibit other peptidases besides ATA, we tried
to antagonize surface ATA activity by a neutralizing monoelonal
anti-murine ATA antibody. As shown in Table 5, Ang 11 is
mitogenic for ATAS and ATA2I cells in the presence of this
antibody. In contrast to findings obtained with Ang II, all tested
cell lines failed to show a change in [3H]thymidine incorporation
compared with baseline values when stimulated with 10—6M Ang
III or Ang IV (Table 6).
DISCUSSION
A growing body of evidence suggests that Ang II is a major
factor in the progression of chronic renal disease [1—71. Tradition-
ally, many studies have focused on the generation of Ang II and
Fig. 2. Northern blot of total RNA from the
clones that were originally positive in the RT-
PCR screening process as well as from mouse
mesangial cells (MMC5) and mock-transfected
Neo3 cells five weeks after transfection. As
predicted, MMCs and Neo3 showed no specific
hybridization for aminopeptidase A (ATA).
However, from the original seven positive
clones, only the cell lines ATA5, ATA 10, and
ATA21 still expressed ATA transcripts
suggesting that the transgene is lost from the
other clones. The slight difference in the size of
the hybridization signal (4.1 kb in mousc) may
he due to transgene integration at different
genomic sites or alternative splicing of mRNA.
all components of the RAS have been characterized on a molec-
ular level. Such studies have lead to the development of an
impressive therapeutic armament to interfere with the actions of
Ang II such as ACE inhibitors, renin antagonists, and Ang
IT-receptor blocker [1—51. However, local concentrations and
homeostasis of Ang IT may not only be determined by the
generation, but also by the metabolism of the octapeptide. One
key enzyme being involved in Ang 11-splitting is ATA, a ho-
modimeric type II membrane-bound peptidase that specifically
cleaves the N-terminal aspartyl residues of Ang II leading to the
generation of Aug III [15, 22, 251. Moreover, ATA may be
involved in the inactivation of angiotensin-(1-7). Renal ATA
localization has been studied by enzyme histochemistry and more
recently with immunohistochemistry [10, 26—281. In general, ATA
expression is present in glomeruli and the brush border of
proximal tubules. In the mouse, the glomerular localization of
ATA is confined to cell membranes of podocytes as assessed by
immunoelectron microscopy [10, 271. No ATA expression was
noted in mesangial cells [10, 26—28]. In the rat, enzyme histo-
chemistry has localized ATA in endothelial cells and podocytes,
but not in mesangial cells [26, 27]. However, recently one group of
investigators claimed that ATA is present in rat mesangial cells
[29, 30]. This singular finding is in contrast to previous studies [26,
27, 31] and certainly requires further confirmation. Nevertheless,
there is no evidence of mesangial expression of ATA in mice [10,
26, 27], and along this line we failed to demonstrate ATA mRNA
in MMCs even by sensitive RT-PCR.
Renal ATA regulation is complex, and in general increases in
ATA mRNA and enzyme activity have been described in patho-
physiological situations with an activated RAS such as diabetes
ATA5
ATA6
ATA1O
ATA1 8
ATA1 9
ATA2O
ATA21
MMC
4.1 kb
18 S
—Fig. 3. Western blots of cellular lysates (100
gllane) probed with the specific monoclonal
anti-mouse ATA antibody ASD-4. A specific
protein band of 130 kDa is present in lysates
from ATA-overexpressing clones ATA5 and
ATA21, but not in MMCs or Neo3 cells. This
blot was repeated twice with qualitatively
similar results.
mellitus, furosemide treatment, and after nephrectomy [22, 32,
33]. Moreover, direct infusion of Ang II into rats induces glomer-
ular ATA expression in naive rats [3I. Studies using human
glomerular epithelial cells have demonstrated that ATA activity
was stimulated by forskolin and isobutylmethlyxanthine, suggest-
ing a potential role of cAMP as a second messenger in ATA
regulation [25].
Our MMCs stably transfected with ATA exhibit abundant ATA
mRNA and protein, in contrast to wild-type MMCs or mock-
transfected Neo3 cells in which ATA expression is totally absent.
Although there was some very low enzyme activity in MMCs using
the substrate alpha-glutamyl-nitranilide, which may be also partly
utilized by other peptidases being present in mesangial cells such
as aminopeptidase N [25], there was a clear increase in enzyme
activity in ATA5 and ATA21 cells. However, a formal determi-
nation that ATA-overexpressing cells generate more Ang III
requires the isolation and identification of the peptide fragments
by high-pressure liquid chromatography, experiments which are
beyond the scope of this study. Since we are interested in potential
growth-promoting effects of Ang II, we studied the mitogenic
effects of the octapeptide in MMCs. Although there is some
debate as to whether Ang II stimulates mitosis or hypertrophy in
cultured mesangial cells, depending on cell culture conditions and
species, both growth responses are induced under distinct condi-
tions [11, 35—40]. We have previously shown that Ang II causes a
small, but significant proliferative effect in MMCs [11, 12]. Other
investigators have confirmed these data in mouse, rat and fetal
human mesangial cells [35, 39, 40]. There is some evidence that
this proliferative effect may be mediated by endogenous release of
interleukin 6 [35]. Ang II failed to stimulate proliferation in ATA5
and ATA21 clones as measured by incorporation of [3H]thymi-
dine and total cell counts. In contrast, in mock-transfected Neo3
cells Ang II has similar mitogenic effects as in wild-type MMCs,
suggesting that the transformation and selection process per se is
not responsible for this difference. Furthermore, other mitogens
such as FCS stimulate proliferation in ATM and ATA21 compa-
rably to the mitogenesis observed in MMCs, indicating that the
failure to proliferate in ATA-overexpressing cells is not an
intrinsic defect in cell cycle regulation. There was no major
difference in binding characteristics of Ang II in the various cell
lines making differences in AT1-receptor expression unlikely. The
probably most direct evidence that ATA is actually responsible for
the observed difference stems from our amastatin and anti-ATA
antibody experiments. In the presence of this ATA-inhibitor, Ang
II is mitogenic for ATA5 and ATA21 cells, revealing that inhibi-
tion of surface ATA is sufficient to observe a proliferative effect of
Ang II in these cells. However, amastatin may also interfere with
the activity of other peptidases besides ATA, and more specific
ATA inhibitors have been recently developed [41]. We used an
alternative approach to inhibit surface ATA more specifically with
a neutralizing anti-murine ATA antibody. It has been previously
demonstrated that this antibody binds to the active center of ATA
and inhibits enzyme activity [23, 24, 42]. Ang II was mitogenic for
ATA5 and ATA21 cells in the presence of this antibody, under-
scoring further that enzyme inhibition is necessary for Ang II to
become mitogenic. This was not due to nonspecific effects because
the antibody was also included in the control medium.
All tested cell lines (MMC, Neo3, ATA5, and ATA21), in
contrast to findings obtained with Ang II, revealed no change in
baseline proliferation when stimulated with Ang III or Ang IV.
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MMC
Neo3
ATA5
ATA21
200 kDa
97.4 kDa

TabJe 2. Total cell counts 48 hours after a single dose of Ang II
Cell line Cell count X1f cells/well
Neo3
Controls
10-6 M Ang JJ
ATA5
Controls
106 M Ang JJ
ATA21
Controls
M Ang II
________________
N = 6. a p < 0.01 versus controls
Fig. 5. Expression of Ang Il-receptors in the different cell lines. (A)
Displacement experiments of [3H] Ang II with cold competitor revealed
no major difference in Ang II binding in MMC ATA5 (I), and
ATA2I (•) cells. The mean values of four independent experiments with
duplicate measurements are shown. (B) eDNA amplication of reverse
transcribed RNA using primers for AT1-receptors or p-actin. Compared
with the expression of p-actin, there was some variations in AT1-receptor
transcripts with more expression in ATA2I cells and MMCs. This
experiment was performed four times with qualitatively similar results.
Furthermore, Ang III did not stimulate 1P5 generation in ATA2I
cells. Although it is generally assumed that Ang III binds to the
same receptors as Ang II [1, 51, our findings suggest that the
affinity of Ang III for AT1-reeeptors may he considerably lower
than that of Ang II. Since mesangial cells may abundantly express
APN [281, an enzyme that can metabolize Ang III [25], an
additional explanation of the failure of Ang III to stimulate
proliferation may be the fast degradation of this peptide. There is
recent evidence that specific receptors for Ang IV exist in human
collecting duct and bovine endothelial cells in which this peptide
may have fundamentally different effects than Ang II or Ang III
[43—45]. However, there is currently no indication that similar
receptors are expressed in mesangial cells, and Ang IV failed to
either stimulate or inhibit mitosis in the present study. Thus,
based on our results obtained with Ang 111 and Ang IV, it appears
that the lack of proliferation after Ang II challenge in ATA5 and
ATA2I clones is indeed due to a decrease in Ang II and not due
to anti-mitogenic effects of newly generated Ang III or Ang IV.
In addition to the more long-term effects of proliferation, Ang
II failed to increase intracellular 1P3, a typical second messenger
for Ang II in mesangial cells [46], in ATA-overexpressing clones,
but not in Neo3 cells. However, Ang II stimulated 1P3 generation
in ATA-overexpressing cells in the presence of the ATA neutral-
izing antibody. These findings suggest that Ang II is rather rapidly
metabolized in ATA-overexpressing cells because 1P5 induction
occurs shortly after binding of the peptide to its receptor. The
neutralizing ATA antibody presumably inhibits enzyme activity,
thus making Ang II accessible for its receptor. Less likely alter-
native explanations that cannot be totally ruled out, however, are
an alteration of Ang IT-associated signal transduction pathways in
ATA5 and ATA2I clones, or a very high affinity of ATA for Ang
II so that all of the peptide may bind to the enzyme instead of
AT1-receptors.
Since an impressive therapeutic armament exists to interfere
with the RAS, including Ang Il-receptor antagonists and ACE-
inhibitors, one may ask why to overexpress ATA in order to
A
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Table 1. Intracellular 1P3 concentrations after stimulation with 106 M
Ang II or Ang III for 10 minutes
0)C
11)>
0
00
0
0)C0C
100
50
0
1P3 pmol/1O cellsCell line
Neo3
Controls 4.3 1.3
Ang II 15.9 2.6l
ATA5
Controls 5.6 1.2
Ang II 4.8 1.2
ATA2I
Controls 4.1 1.6
Aug11 4.5±1.1
Controls + moAb 3.8 1.0
Ang II + moAb 13.1 2.4a
Ang ITT
-__________________________
4.4 0.9
Abbreviations are: 1P3, 1,4,5-triphosphate; Ang, angiotensin; moAb,
neutralizing anti-ATA monoclonal antibody. N = 4.5 (N = 3 for experi-
ments with moAb).
a P < 0.05 versus controls and moAb
0 —10 9 —8 'P < 0.01 versus controls
B ____________________________________________
Log M Ang II
AT1 -,
3-actin -+
130 9.0
193 6.3k'
125 5.6
131 4.2
91 2.8
87 5.1
Fig. 4. Immunoflnorescence staining for ATA applying the ASD-4 antibody. (A) No specific staining for ATA protein could he detected in wild-type
MMCs. (B) In contrast, ATA5 cells revealed a strong nuclear as well as membrane staining. The exposure time for A. was twice as long as for picture
B (magnification X200).
S a — a
*I *-I- *
T
Cell line
Controls 10% FCS 2 % FCS
X/04 cpm
MMC 7.1 0.7 120.1 31h 15.2 1.oa
ATA5 9.4 0.9 102.3 17.0 2.1a
ATA2I 4.7 0.4 115.9 536 10.1 0.8
N = 8 to 10.
a f < 0.01, 6 P < 0.001 versus controls
Table 4. Effect of 0.1 mvi amastatin on Ang 11-stimulated [3H1
thymidine incorporation in ATA5 and ATA21 cells
[3H} thymidine
Cell line X]04 cpm
ATA5
Controls
Controls + amastatin
iO M Ang II
10 M Ang II + amastatin
ATA2I
Controls
Controls + amastatin
i0 at Ang 11
10 i Ang II + amastatin
N = 10.
P < 0.05 versus controls + amastatin
Fig. 6. [3H] thymidine incorporation into DNA
as one measurement of proliferation. Cells were
incubated for 24 hours with a single dose of
iO to 10-6 vi Ang 11 in the absence of other
factors. As predicted from earlier experiments
[111, Ang II stimulated proliferation in MMCs
(LI) and mock-transfected Neo3 cells (LI).
However, the vasoactive peptide failed to
induce mitogenesis in ATAS (LI) and ATA2I
() cells. There was even a tendency in ATM
cells that ANG II may cause inhibition of
proliferation, although the values did not reach
statistical significance. N = 10, *p < 0.05 versus
unstimulated controls.
Table 5. Effect of a neutralizing anti-murine ATA monoclonal antibody
on Ang lI-stimulated [3H] thymidine incorporation in ATA5 and
ATA2I cells
Cell line x104 cp
ATA5
Controls + moAb
10' vi Ang II
i0 M Ang II + moAb
ATA21
Controls + moAb
106 M Aug II
106 M Aug II + moab
Abbreviations are: Ang, angiotensin; moAb, neutralizing anti-ATA
monoclonal antibody.
P < 0.05 versus Aug II only
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10
8
0
x
4
2
0
Controls 1 0 M 1 0 M
Table 3. Effect of FCS (10% or 2%) on [3Hj thymidine incorporation
8.1 0.7
6.5 0.5
10.2 0.6k'
7.0 0.9
6.8 0.5
12.2 1.la
7.0 0.6
4.7 0.4
6.8 0.4
8.0 1.3
5.8 0.5
7.5 0.9
6.6 0.5
12.1 1.Oa
receptors including AT2 [48]. Although this effect could be
protective since AT2-receptor activation has been associated with
antigrowth effects in some tissue [49, 501, there is little evidence of
this mechanism in renal tissue. Furthermore, we have recently
provided evidence that stimulation of AT2-receptors in glomeru-
lar endothelial cells induces the synthesis of the chemokine
RANTES, a strong chemoattractant substance for macrophages!
monocytes [51]. Treatment with ACE inhibitors as well as with
AT1 -receptor antagonists stimulates renin synthesis. Recent evi-
dence suggests that renin directly binds to mesangial cells, stim-
ulates proliferation, and increases plasminogen activator inhibi-
tor-i antigen, which are undesired effects that may occur during
hyperreninemia [52]. Thus, overexpression of ATA spatially ad-
jacent to Ang Il-receptors may locally inactivate Ang II without
influencing RAS, providing some advantages over other therapeu-
tic manipulations. However, since Ang III, the product of ATA-
mediated Ang II metabolism, may also bind to AT1-receptors,
ATA overexpression in vivo would be only successful if Ang III is
directly further cleaved to inactive fragments. In addition, we have
antagonize Aug Il's effects. However, the currently employed
drugs to intervene with the RAS may have some disadvantages.
For example, it remains unclear whether ACE inhibitors in the
commonly used dosage totally inhibit local tissue ACE activity
[2—4]. In addition, ACE may be bypassed and active Aug II can be
formed by other enzymes such a chymase [47]. On the other hand,
blockade of the AT1-receptor may shift binding of Ang 11 to other
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Table 6. Effect of angiotensin III (Ang III) and angiotensin IV (Ang
IV) on [3H] thymidine incorporation
Cell line ><iO cpm
MMC
Controls 8.5 0.6
i0 M Ang III 9.1 0.5
10—6 M Ang IV 8.2 0.2
Neo3
Controls 6.5 0.6
i0 M Ang III 7.0 0.8
10 M Ang IV 6.0 0.7
ATA5
Controls 8.0 0.2
10' M Ang III 6.7 0.2
10—6 M Ang IV 9.0 0.3
ATA21
Controls 7.9 0.5
10—6 M Ang III 7.5 0.2
-
IIY6MAngIV 8.3±0.7
N = 10 to 12.
overexpressed ATA in SV 40-transformed mesangial cells and it is
currently unclear if this enzyme could be adequately overex-
pressed in normal mesangial cells residing in the glomerular
microenvironment. Therefore, it remains to be established
whether ATA-overexpression may be effective in vivo.
In summary, overexpressing of ATA in mesangial cells abol-
ished the proliferative effects of Ang II on these cells. Our
experiments are a first step toward the development of novel
strategies to selectively interfere with a locally activated RAS.
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APPENDIX
Abbreviations used in this study are: Ang, angiotensin; ATA, amino-
peptidase A; MMC, mouse mesangial cell line; RAS, renin-angiotensin
system; 1P3, 1,4,5-triphosphate; ACE, angiotensin converting enzyme;
PBS, phosphate buffered saline; dNTP, deoxynucleotide triphosphate;
PMSF, phenylmethylsulfonyl fluoride.
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